title: Efficiency of antiviral therapy plus IVIG in a case of primary EBV infection associated PTLD refractory to rituximab, chemotherapy, and antiviral therapy alone.
authors.forename: R
authors.initials: R
authors.lastname: Trappe
authors.forename: H
authors.initials: H
authors.lastname: Riess
authors.forename: I
authors.initials: I
authors.lastname: Anagnostopoulos
authors.forename: R
authors.initials: R
authors.lastname: Neuhaus
authors.forename: B C
authors.initials: BC
authors.lastname: Gärtner
authors.forename: H
authors.initials: H
authors.lastname: Pohl
authors.forename: H P
authors.initials: HP
authors.lastname: Müller
authors.forename: S
authors.initials: S
authors.lastname: Jonas
authors.forename: M
authors.initials: M
authors.lastname: Papp-Vary
authors.forename: S
authors.initials: S
authors.lastname: Oertel
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000998:Antiviral Agents / Q000627:therapeutic use*; D020031:Epstein-Barr Virus Infections / Q000150:complications / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000627:therapeutic use*; D007167:Immunotherapy; D016031:Liver Transplantation; D008232:Lymphoproliferative Disorders / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology / Q000821:virology; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000998:Antiviral Agents; D016756:Immunoglobulins, Intravenous; D000069283:Rituximab